On December 4, 2024 Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector development and manufacturing, reported a strategic partnerships with Treovir (Press release, Treovir, DEC 4, 2024, View Source [SID1234648816]). The collaboration aims to advance innovative therapies for pediatric patients with brain and other neurological cancers. Matica Bio will provide GMP manufacturing for clinical supplies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Treovir, a biotechnology company developing oncolytic immunotherapies, will partner with Matica Bio on its G207 HSV-based oncolytic therapy for treating glioblastoma and other brain tumors in children. The therapy is currently in Phase 2 clinical trials and could ultimately provide a treatment option for children in this critically underserved therapeutic area. "Finding a CDMO partner who truly understands our mission and works alongside us as an extension of our team is essential for successful drug development," said Michael Christini, CEO of Treovir. "We are collaborating with Matica Bio on process optimization and GMP clinical production for G207 and we look forward to advancing this promising therapy for pediatric brain tumors with Matica Bio playing a key role."
Matica Bio is committed to leveraging its expertise in gene therapy development and manufacturing to support the creation of treatment that address the unique challenges faced by children with rare diseases.
"We are thrilled to partner with Treovir in this important effort," said Paul Kim, CEO of Matica Bio. "Pediatric rare diseases represent an area of critical need, and Matica Bio is proud to contribute to the mission of improving the lives of these children. Our cutting-edge facilities and advanced manufacturing technologies provide the ideal foundation to help bring these life-changing therapies to market."
The collaboration reflects a shared commitment to addressing critical gaps in pediatric healthcare, ensuring that no child is left behind in the pursuit of better health outcomes.